Abstract: A method is described for reconstituting lyophilized mutant diphtheria toxin in dimethyl sulfoxide for use in producing pneumococcal capsular polysaccharide mutant diphtheria toxin conjugates.

Abstract: Embodiments disclosed herein relate to a model for predicting the release profile of a controlled release device. The implant modeling system and models disclosed herein allow the accurate prediction of a release profile for a controlled release device based on features extracted from micro-resolution imagery. The models combine microstructural features that can be extracted at the XRCT resolution, including pore volume and connectivity, using erosion-dilation image analysis. This strategy allows prediction of release curves of the controlled release device using XRCT despite its resolution limitations.

Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.

Abstract: To provide a photosensitive siloxane composition capable of forming a pattern having a desired taper angle and a desired linewidth. [Means] The present invention provides a photosensitive siloxane composition comprising: a polysiloxane having a structure represented by the following formula (ia?): (L is an alkylene or phenylene), a photoactive agent, and a solvent.

Abstract: New compounds and their mixtures enable the formation of the ferroelectric nematic liquid crystalline phase at ambient temperature. Compounds of the formula I are presented, in which the variable groups have the meanings indicated in claim 1. Liquid crystal media comprise at least one compound of the formula I.

Abstract: The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, prevention, or prophylaxis of HCMV in a patient. In addition, the invention also provides methods for making the mini-tablets of the invention.

Abstract: The present invention relates to a cation exchange chromatography process for the purification of enteroviruses.

Abstract: Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.

Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

Abstract: Isothiocyanato tolane derivatives of formula I-1 and liquid-crystalline media comprising same are suitable for use in high-frequency components, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, in particular for microwave phased-array antennas.

Abstract: Alpha-Alumina flakes having a particle thickness of 130-400 nm, a D50-value of 15-30 ?m, a D90-value of 30-45 ?m and a D10-value of <9.5 ?m. Use of the alumina flakes in varnishes, paints, automotive coatings printing inks, masterbatches, plastics and cosmetic formulations. Also, use of the alumina flakes as a substrate for effect pigments and in organic dyes.

Abstract: Alpha-Alumina flakes having a particle thickness of 130-400 nm, a D50-value of 15-30 ?m, a D90-value of 30-45 ?m and a D10-value of <9.5 ?m. Use of the alumina flakes in varnishes, paints, automotive coatings printing inks, masterbatches, plastics and cosmetic formulations. Also, use of the alumina flakes as a substrate for effect pigments and in organic dyes.

Abstract: The present invention describes carbazole, dibenzofuran, dibenzothiophene and fluorene derivatives which are substituted by electron-deficient heteroaryl groups, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising these compounds.

Abstract: A method for processing digital image recognition of invariant representations of hierarchically structured entities can be performed by a computer using an artificial neural network. The method involves learning a sparse coding dictionary on an input signal to obtain a representation of low-complexity components. Possible transformations are inferred from the statistics of the sparse representation by computing a correlation matrix. Eigenvectors of the Laplacian operator on the graph whose adjacency matrix is the correlation matrix from the previous step are computed. A coordinate transformation is performed to the base of eigenvectors of the Laplacian operator, and the first step is repeated with the next higher hierarchy level until all hierarchy levels of the invariant representations of the hierarchically structured entities are processed and the neural network is trained. The trained artificial neural network can then be used for digital image recognition of hierarchically structured entities.

Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.

Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.

Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: A liquid-crystalline medium having least one compound of the formula I, and at least one compound of the formulae ST-1 to ST-17, in which R1 and R1*, A1 and A1*, Z1 and Z1*, X, L1 and L2, RST, ring A, ZST, p and q have the meanings indicated in claim 1, and the use thereof for an active-matrix display, in particular based on the VA, PSA, PA-VA, SS-VA, SA-VA, PS-VA, PALC, IPS, PS-IPS, UB-FFS, U-IPS, FFS or PS-FFS effect.

Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.